Latest Commercial Execution News

EBR Systems reported 40 WiSE commercial implants in Q3, down from 46 in Q2 and below its prior forecast, as leadership changes and a sales strategy reset disrupted activity. Higher Medicare reimbursement and progress at its new manufacturing facility offer potential offsets, but both remain dependent on execution and regulatory approval.

Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.

Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.

Lake Resources has secured the primary provincial environmental permit for its Kachi lithium project in Argentina, clearing the way for detailed engineering and financing work. The approval removes a major development hurdle, but FEED, funding, RIGI approval and a final investment decision remain ahead.

EBR Systems has completed the FDA’s pre-approval inspection of its new Santa Clara manufacturing facility, receiving two Form 483 observations. The company says it expects to correct them in the fourth quarter and still anticipates approval by year-end, although the FDA has not yet made its final determination.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

Dataworks has completed a A$3.0 million placement, issuing 25 million shares at A$0.12 each as it moves to fund working capital, government program delivery and platform development. Shareholders now face the next stage of the raising, with a 1-for-10 entitlement offer opening on 28 September.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.

Adisyn has moved closer to commercialising its graphene platform after independently verified sub-300°C deposition, a US patent allowance and a new defence technology arm. The progress came alongside a A$7.83 million statutory loss, A$4.47 million in operating cash outflows and a heavily judgement-based A$42.1 million technology asset.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

Vulcan Energy has started commercial-scale production in Germany of VULSORB, the proprietary adsorbent at the centre of its planned direct lithium extraction process. The material will supply first-fill volumes for Project Lionheart, although lithium production remains targeted for the second half of 2028.

Dataworks Group has lodged a prospectus for a non-renounceable entitlement offer targeting A$1.24 million, alongside a committed A$3 million placement. The raising would fund debt repayment, working capital and contract mobilisation, but also materially expand the company’s share count and option pool.